Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03611270
NCT03611270Active, not recruitingNot Applicable

Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Pulmonary Artery Denervation in Patients With Pulmonary Hypertension Due to Left Heart Disease

SoniVie Inc.3 sites in 1 country15 target enrollmentStarted: November 30, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
15
Locations
3
Primary Endpoint
Procedural related Adverse Events (complications) at up to 30 days post procedure
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The objective of this study is to assess the safety and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation in group II PH patients through change in clinical parameters including hemodynamics, exercise tolerance, and quality of life.

This is a prospective, multi-center, non-randomized, open-label clinical trail. The study will be conducted in up to 3 centers and will recruit up to 15 patients diagnosed with pulmonary hypertension due to left heart disease that demonstrate combined pre and post capillary involvement with PVR>3 wood units.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Written informed consent to participate in the study obtained from the patient, according to local regulations, prior to initiation of any study mandated procedure.
  • •Male or female, ≥ 18 years of age at the time of screening
  • •Patient with known pulmonary hypertension (PH) due to left heart disease (WHO Group II) diagnosed as either HFpEF or HFrEF at chronic state receiving stable guideline directed medical therapy.
  • •Combined post-capillary and precapillary pulmonary hypertension diagnosis confirmed by hemodynamic evaluation performed prior to screening or during baseline (Eligibility II visit) procedure
  • •Patient with a current diagnosis of NYHA functional class II/III
  • •Patient with eGFR levels of ≥ 30 ml/min/1.73m2or serum creatinine levels of ˂ 150μmol/l

Exclusion Criteria

  • •Pregnant women or women planning a pregnancy within 12 months of study enrolment
  • •Patient with significant co-morbid condition(s) which, at the discretion of the PI, are deemed to prohibit study entry
  • •Patient with life expectancy of less than a year
  • •Concurrent enrollment in another device or drug trial except for observational studies (unless specifically approved by the sponsor)
  • •Patient with pulmonary artery anatomy that precludes treatment
  • •Patient with moderate to severe pulmonary artery stenosis
  • •Patient with any pulmonary artery aneurysm
  • •Patient who has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident in the previous 6 months
  • •Patient experiencing a current episode of acute decompensated heart failure
  • •Patient who has cardiac pacemakers/ICD/CRT-D that were implanted fewer than three months prior to enrolment. Patient who has implantable Cardiomems device, neurostimulators or drug infusion devices, regardless of implant date.

Outcomes

Primary Outcomes

Procedural related Adverse Events (complications) at up to 30 days post procedure

Time Frame: 30 days

Procedural related Adverse Events (complications) at up to 30 days post procedure including pulmonary artery perforation/dissection, acute thrombus formation in the pulmonary artery, pulmonary artery aneurysm, vascular stenosis, hemoptysis, all cause PH related as well as procedural related death.

Secondary Outcomes

  • Change in resting mean right atrial pressure(4 month)
  • Change in NT-BNP levels(4 month)
  • Change in exercise mean pulmonary artery pressure(4 month)
  • Change in resting cardiac index(4 month)
  • Change in exercise pulmonary vascular resistance(4 month)
  • Changes in cardiopulmonary exercise test(4 month)
  • Changes in Echocardiography parameters(4 month)
  • Changes in 6MWD from baseline(4 month)
  • Change in exercise mean right atrial pressure(4 month)
  • Change in resting mean pulmonary artery pressure(4 month)
  • Procedure related and PH worsening adverse events(12 month)
  • Change in resting pulmonary vascular resistance(4 month)
  • Change in exercise cardiac index(4 month)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
TReatment Of Pulmonary HYpertension 1-US StudyPulmonary Arterial Hypertension
NCT02835950SoniVie Inc.15
Unknown
Not Applicable
TReatment Of Pulmonary HYpertension 1 StudyPulmonary Arterial Hypertension
NCT02516722SoniVie Inc.15
Unknown
Phase 2
Continued Safety and Performance of the TIVUS SystemHypertension, Resistant to Conventional Therapy
NCT01835535Cardiosonic80
Not yet recruiting
Not Applicable
TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal StudyPulmonary Arterial Hypertension
NCT04570228SoniVie Inc.205
Active, not recruiting
Not Applicable
REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /Uncontrolled Stage 2 Hypertension
NCT05372679SoniVie Inc.25